Andreas Kovar

Sanofi R&D
Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Designing integrated early-phase protocols to reduce substantial modifications, including considerations for patient cohorts - a multi-stakeholder consensus view for a practical approach in Germany.

Designing integrated early-phase protocols to reduce substantial modifications, including considerations for patient cohorts - a multi-stakeholder consensus view for a practical approach in Germany.

Journal: Frontiers in pharmacology

Published: September 05, 2025

Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference.

Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference.

Journal: CPT: pharmacometrics & systems pharmacology

Published: December 19, 2024

First-in-Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants.

First-in-Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants.

Journal: Clinical pharmacology and therapeutics

Published: November 20, 2024

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease.

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease.

Journal: The Journal of pharmacology and experimental therapeutics

Published: November 16, 2022

LaTeX tutorial for the standardization and automation of population analysis reports.

LaTeX tutorial for the standardization and automation of population analysis reports.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 01, 2020

Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences.

Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences.

Journal: CPT: pharmacometrics & systems pharmacology

Published: June 20, 2019

Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.

Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.

Journal: Journal of clinical pharmacology

Published: December 04, 2014

Population pharmacokinetics of cilengitide in adult and pediatric cancer patients from a nonlinear mixed-effects analysis.

Population pharmacokinetics of cilengitide in adult and pediatric cancer patients from a nonlinear mixed-effects analysis.

Journal: Journal of clinical pharmacology

Published: February 10, 2014

Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses.

Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses.

Journal: Investigational new drugs

Published: September 12, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026